title: [Quantitative detection of differential display code 3 mRNA in peripheral blood of patients with prostate cancer].
abstract: OBJECTIVE
  To investigate the expression of DD3 mRNA in the peripheral blood and its value in diagnostic of prostate cancer (Pca).
  
  
  METHODS
  Thirty-five untreated Pca patients, aged 72 (53 - 83), 58 Pca patients treated with endocrinotherapy, aged 74 (53 - 86), and 59 patients with benign prostatic hyperplasia, aged 71 (48 - 85), underwent peripheral blood sample collection one week before or after digital examination. RT-PCR was used to examine the level of DD3 mRNA. The level of prostate specific antigen (PSA) was detected too. Ten healthy male frontiers, aged 33 (21 - 38), were used as controls. Receiver operating curve (ROC) was drawn to evaluate the diagnostic performance of DD3 mRNA.
  
  
  RESULTS
  The DD3 mRNA level of the untreated Pca patients was 2741 copies/ml, significantly higher than those of the Pca patients treated with endocrinotherapy, patients with benign hyperplasia, and healthy persons (all < 24 copies, all P < 0.001). The DD3 mRNA level of the endocrinotherapy-treated Pca patients was significantly higher than those of the patients with benign hyperplasia, and healthy persons (both P < 0.001). ROC analysis showed that when the critical value was 846 copies/ml the area under curve of ROC (AUC-ROC) was 0.8233 (95% CI: 0.725 - 0.910). and the sensitivity was 74.34%, the specificity was 89.8%. The DD3 mRNA in the peripheral blood increased along with the increase of clinical staging (P < 0.01).
  
  
  CONCLUSIONS
  The level of DD3 mRNA in the peripheral blood is an excellent marker for diagnosis pf Pca, and may help in monitoring of the curative effects of endocrinotherapy.
authors.affiliation: Department of Urology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
authors.forename: Zhi-Liang
authors.initials: ZL
authors.lastname: Weng
authors.forename: Kai-Yuan
authors.initials: KY
authors.lastname: Yu
authors.forename: Xiao-Lu
authors.initials: XL
authors.lastname: Mao
authors.forename: Zhi-Hua
authors.initials: ZH
authors.lastname: Tao
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Chen
authors.forename: Xiu-Ling
authors.initials: XL
authors.lastname: Wu
authors.forename: Yuan-Ping
authors.initials: YP
authors.lastname: Hu
authors.forename: Si-Qi
authors.initials: SQ
authors.lastname: Wang
authors.forename: Cheng-di
authors.initials: CD
authors.lastname: Li
authors.forename: Zhan-Guo
authors.initials: ZG
authors.lastname: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000097:blood; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000235:genetics; D012333:RNA, Messenger / Q000097:blood* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D012333:RNA, Messenger; C479341:prostate cancer antigen 3, human; D017430:Prostate-Specific Antigen